US Biotech Stocks Surge... CEOs Buy Large Amounts of Company Shares

Recently, in the US stock market, the stock prices of biotech companies have surged sharply, and it has been reported that some biotech company CEOs have also purchased shares of their own companies.

[Image source=Pixabay]

On the 25th (local time), US economic media Barron's reported, "Some biotech companies have seen their stock prices soar this year, and some CEOs are taking advantage of this," adding, "CEOs of biotech companies such as Seebus, OmniAB, and Liquidia have spent millions of dollars to acquire additional shares." These three companies are small-cap stocks with market capitalizations under $1 billion (approximately 1.3 trillion KRW). Their stock price increases this year have significantly outperformed the Standard & Poor's (S&P) 500 index (24%). The rise has been especially notable since the end of last month.

Seebus is an agricultural technology company that develops plant traits and licenses them to seed companies in exchange for royalties. Its market capitalization is approximately $416.7 million (about 509.6 billion KRW). The stock price has fluctuated due to merger and acquisition issues this year. Earlier this month, it raised capital by issuing 2.1 million shares at $9 per share through a stock offering and issued warrants allowing the purchase of up to 500,000 shares. The stock price has surged about 69% over the past eight trading days. Co-CEO Lori Riggs purchased approximately 517,000 shares at $10.58 per share, higher than the offering price, spending about $5.5 million (approximately 7.12 billion KRW) on the 12th. She also acquired warrants worth about $528,500 (approximately 684.4 million KRW).

OmniAB is a company developing human therapeutic candidate substances. Its market capitalization is about $674.2 million (approximately 873 billion KRW), and its stock price has risen 61% this year. CEO Matt Foehr purchased an additional 200,000 shares of the company for $1 million (approximately 1.29 billion KRW) on the 12th. He holds about 2.6 million shares and also owns restricted stock and stock options.

Liquidia is a biotech pharmaceutical company focused on pulmonary hypertension treatment. Its stock price has risen more than 80% this year and surged about 70% compared to the closing price on the 5th. On the 12th, it conducted a stock offering worth $3.5 million (approximately 4.53 billion KRW) at $7.16 per share, and CEO Roger Jeffs purchased about 140,000 shares worth $1 million.

This content was produced with the assistance of AI translation services.